# Magnoflorine (from Tinospora cordifolia, Sinomenium acutum, and related plants)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/magnoflorine-from-tinospora-cordifolia-sinomenium-acutum-and-related-plants
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** MGN, Magnoflorine iodide (salt form), Quaternary aporphine alkaloid, Corytuberine methyl betaine (historical synonym)

## Overview

Magnoflorine (MGN) is a quaternary aporphine alkaloid that modulates NF-κB, TLR4/MyD88, MAPK (JNK, ERK, p38), and Akt signaling cascades to exert context-dependent [immunomodulatory](/ingredients/condition/immune-support), [anti-inflammatory](/ingredients/condition/inflammation), [antioxidant](/ingredients/condition/antioxidant), and anticancer effects across multiple preclinical models. In cancer cell line studies, MGN induced caspase-3-mediated apoptosis in 24.02% of T98G glioblastoma cells at 10 mg/mL (p<0.05) and arrested cell cycle progression at S/G2 phase in lung, breast, glioma, and rhabdomyosarcoma lines, though no human clinical trials have yet validated these findings.

## Health Benefits

- **[Immunomodulat](/ingredients/condition/immune-support)ion**: MGN significantly stimulates macrophage migration and phagocytic activity in RAW 264.7 cells, outperforming other alkaloids from Tinospora cordifolia extracts in immunostimulatory assays, suggesting a role in innate immune enhancement.
- **Anti-inflammatory Activity**: In LPS-induced acute lung injury models in BALB/c mice, MGN reduces TLR4, NF-κB p65, and MAPK phosphorylation while lowering myeloperoxidase activity and histopathological tissue damage, indicating meaningful anti-inflammatory potential in vivo.
- **Anticancer Effects**: MGN inhibits proliferation and induces apoptosis in NCI-H1299 non-small cell lung, MDA-MB-468 breast, T98G glioblastoma, and TE671 rhabdomyosarcoma cell lines, with caspase-3 activation reaching 24.02% in glioma cells at 10 mg/mL (p<0.05), and S/G2 cell cycle arrest observed across lines.
- **Antioxidant Properties**: MGN inhibits [lipid peroxidation](/ingredients/condition/antioxidant) and scavenges free radicals in biochemical assay models, contributing to cytoprotective effects that may underpin its broader anti-inflammatory and antidiabetic actions at the cellular level.
- **Antidiabetic Preclinical Activity**: Consistent with its source plants' traditional use in managing metabolic disorders, MGN is reported in review literature to exhibit antidiabetic properties in preclinical models, likely through oxidative stress reduction and [inflammatory pathway](/ingredients/condition/inflammation) modulation relevant to [insulin resistance](/ingredients/condition/weight-management).
- **Antimicrobial Activity**: Preclinical data indicate MGN exerts antimicrobial effects against select bacterial and fungal strains, consistent with the broad bioactivity profile of aporphine-class alkaloids, though specific MIC values and pathogen spectra require further characterization.
- **[Neuroprotective](/ingredients/condition/cognitive) Potential**: MGN's capacity to suppress NF-κB-driven neuroinflammatory cascades and its demonstrated cytostatic effects in glioblastoma cells suggest exploratory neuroprotective relevance, warranting dedicated mechanistic investigation in neuronal model systems.

## Mechanism of Action

Magnoflorine exerts its [immunomodulatory](/ingredients/condition/immune-support) and pro-inflammatory effects in LPS-activated macrophages by binding to TLR4/MyD88 receptor complexes, triggering dose-dependent phosphorylation of IKKα/β, IκBα ubiquitination, and nuclear translocation of NF-κB p65, which upregulates downstream cytokines TNF-α, IL-1β, and IL-6 alongside COX-2-mediated PGE2 production, with concurrent activation of Akt and MAPK branches (JNK1/2, ERK1/2, p38). Paradoxically, in the context of LPS-induced acute lung [inflammation](/ingredients/condition/inflammation) in vivo, MGN suppresses these same TLR4-MAPK-NF-κB axes, reducing myeloperoxidase activity and tissue damage, suggesting that its net signaling output is concentration- and context-dependent. Its anticancer mechanism involves induction of intrinsic apoptosis via caspase-3 activation and S/G2 phase cell cycle arrest, likely through disruption of cyclin-dependent kinase regulation, as demonstrated across four cancer cell lines in vitro. [Antioxidant activity](/ingredients/condition/antioxidant) proceeds through direct radical scavenging and inhibition of lipid peroxidation chain reactions, providing a complementary cytoprotective mechanism that may attenuate oxidative drivers of both inflammation and metabolic dysregulation.

## Clinical Summary

No human clinical trials investigating magnoflorine as an isolated compound have been conducted or reported in the peer-reviewed literature available through 2024. All quantitative efficacy data originate from preclinical in vitro and rodent in vivo models, which demonstrate dose-dependent [immunomodulatory](/ingredients/condition/immune-support), [anti-inflammatory](/ingredients/condition/inflammation), and anticancer effects but cannot be directly extrapolated to human therapeutic doses or clinical outcomes. The absence of pharmacokinetic data in humans means that effective concentrations observed in cell culture (e.g., 10 mg/mL antiproliferative) have no established human dosing equivalent, and oral bioavailability of this quaternary alkaloid remains uncharacterized. Confidence in clinical benefit is therefore very low; MGN remains a candidate compound for future first-in-human studies rather than a clinically validated intervention.

## Nutritional Profile

Magnoflorine is a pure secondary metabolite alkaloid (molecular formula C20H24NO4+, MW 342.41 g/mol as the cation) and does not contribute macronutrients, micronutrients, vitamins, or caloric value in any meaningful sense when consumed as part of whole-plant preparations at typical doses. As a quaternary ammonium compound with a permanently charged nitrogen, its physicochemical properties suggest limited passive membrane permeability and potentially restricted oral bioavailability, characteristics common to quaternary alkaloids that may require active transport mechanisms or [gut microbiome](/ingredients/condition/gut-health) biotransformation. In whole-plant sources like Tinospora cordifolia, MGN co-occurs with berberine, palmatine, jatrorrhizine, tinosporin, and polysaccharides that may influence its solubility, absorption, and biological activity synergistically. Absolute concentrations of MGN in plant material have not been consistently quantified across published sources, making nutritional or phytochemical profiling of dietary exposure currently imprecise.

## Dosage & Preparation

- **Isolated Alkaloid (Research Grade)**: Used in preclinical studies at concentrations from sub-micromolar to 10 mg/mL in vitro; no human equivalent dose established.
- **Tinospora cordifolia Aqueous Extract (Traditional Kwath/Decoction)**: Dried stem 1–3 g boiled in water, filtered, and consumed; MGN is one of multiple alkaloids present but not standardized to specific MGN content.
- **Tinospora cordifolia Standardized Extract (Supplement Form)**: Commercially available as capsules/tablets standardized to total alkaloids (typically 5–10% alkaloid content); MGN fraction unquantified in most products.
- **Sinomenii Caulis (Traditional Chinese Preparation)**: Decocted stem 6–12 g per day in TCM formulations for rheumatic conditions; MGN co-occurs with sinomenine and other alkaloids.
- **No Established Therapeutic Dose**: No regulatory body or clinical guideline has established a specific magnoflorine dose for any indication; supplementation as an isolated compound is not commercially standardized.
- **Timing Notes**: Preclinical [anti-inflammatory](/ingredients/condition/inflammation) studies suggest activity within hours of administration in animal models; human pharmacokinetic timing is entirely unknown.

## Safety & Drug Interactions

Magnoflorine demonstrated no cytotoxicity in RAW 264.7 macrophage cultures across tested concentrations, and preclinical animal studies have not reported acute organ toxicity, suggesting a potentially acceptable short-term safety profile at low doses, though systematic toxicological characterization (LD50, repeat-dose toxicity, genotoxicity) has not been fully published in accessible literature. No specific drug interaction studies have been conducted for isolated magnoflorine; however, its capacity to modulate [NF-κB](/ingredients/condition/inflammation), COX-2, and TLR4 pathways raises theoretical concern for pharmacodynamic interactions with immunosuppressants, NSAIDs, corticosteroids, and chemotherapeutic agents. As a quaternary alkaloid from plants that inhibit cytochrome P450 enzymes, particularly CYP3A4 (relevant for Tinospora cordifolia broadly), pharmacokinetic interactions with drugs metabolized by these enzymes cannot be excluded without dedicated study. No data exist regarding safety in pregnancy, lactation, pediatric populations, or individuals with renal or hepatic impairment, and supplementation with isolated MGN outside of controlled research settings is not recommended given the complete absence of human safety trials.

## Scientific Research

The entirety of magnoflorine's evidence base consists of in vitro cell culture studies and in vivo animal experiments, with no published human clinical trials identified in the available literature as of 2024. In vitro anticancer studies employed NCI-H1299, MDA-MB-468, T98G, and TE671 cell lines with dose-response analyses confirming apoptosis induction (caspase-3 activation 10–24%, p<0.001–0.05 by ANOVA) and cell cycle arrest at tested concentrations up to 10 mg/mL. [Immunomodulatory](/ingredients/condition/immune-support) studies used RAW 264.7 murine macrophages and U937 human monocyte lines, while in vivo [anti-inflammatory](/ingredients/condition/inflammation) data derive from LPS-challenged BALB/c mouse models with histopathological and biochemical endpoints. The evidence base, though mechanistically detailed, is entirely preclinical and carries substantial translational uncertainty; pharmacokinetic profiling in humans, bioavailability studies, and dose-ranging clinical trials are all absent.

## Historical & Cultural Context

Magnoflorine itself was not historically identified as a discrete molecule, but its botanical sources carry deep traditional significance: Tinospora cordifolia (guduchi or giloy) has been documented in Ayurvedic texts including the Charaka Samhita and Sushruta Samhita as a rasayana (rejuvenating tonic) used for fever, jaundice, urinary disorders, and [immune support](/ingredients/condition/immune-support) for over two millennia in the Indian subcontinent. Sinomenium acutum and its processed stem Sinomenii Caulis (Qing Feng Teng) have been employed in Traditional Chinese Medicine for at least 1,000 years primarily to dispel wind-dampness and alleviate joint pain in rheumatic and arthritic conditions, as recorded in the Compendium of Materia Medica (Bencao Gangmu, 1596). Traditional preparation of these plants involved boiling dried stem bark into concentrated decoctions, fermentation, or incorporation into multi-herb formulas, with the intent of harnessing the whole-plant alkaloid matrix rather than any single constituent. Magnoflorine was chemically characterized as a distinct aporphine alkaloid in the 20th century, allowing modern researchers to attribute specific bioactivities to it separately from the complex phytochemical backgrounds of its source herbs.

## Synergistic Combinations

Within Tinospora cordifolia extracts, magnoflorine co-occurs with berberine and palmatine — isoquinoline alkaloids that share overlapping NF-κB and AMPK modulatory activity — suggesting additive or synergistic [immunomodulatory](/ingredients/condition/immune-support) and antidiabetic effects through complementary molecular targets that may be lost when MGN is isolated. In Traditional Chinese Medicine, Sinomenium acutum is routinely combined with anti-rheumatic herbs such as Clematis chinensis and Gentiana macrophylla, which may enhance [anti-inflammatory](/ingredients/condition/inflammation) synergy through combined cyclooxygenase inhibition and cytokine suppression across distinct signaling nodes. [Antioxidant](/ingredients/condition/antioxidant) co-factors such as vitamin C or quercetin could theoretically stabilize MGN's radical-scavenging activity and protect it from oxidative degradation in the gut, but no experimental data currently confirm this interaction in vivo.

## Frequently Asked Questions

### What is magnoflorine and what plants does it come from?

Magnoflorine (MGN) is a quaternary aporphine alkaloid — a permanently charged nitrogen-containing plant secondary metabolite — found predominantly in Tinospora cordifolia (guduchi/giloy) used in Ayurvedic medicine, Sinomenium acutum used in Traditional Chinese Medicine, and related species. It is isolated from the stems, roots, and bark of these plants through solvent extraction and chromatographic purification, and is characterized by the molecular formula C20H24NO4+ with a molecular weight of approximately 342 g/mol.

### Does magnoflorine have proven antidiabetic effects in humans?

No human clinical trials investigating magnoflorine's antidiabetic effects have been published as of 2024; all available antidiabetic evidence is preclinical and derived from in vitro cell models and animal studies. Its antidiabetic potential is proposed to operate through reduction of oxidative stress and modulation of inflammatory pathways (NF-κB, MAPK) that contribute to insulin resistance, consistent with the traditional antidiabetic use of its source plant Tinospora cordifolia, but human dose-response and efficacy data are entirely lacking.

### What are the anticancer effects of magnoflorine in research studies?

Preclinical in vitro studies show that magnoflorine inhibits proliferation and induces apoptosis in NCI-H1299 non-small cell lung cancer, MDA-MB-468 triple-negative breast cancer, T98G glioblastoma, and TE671 rhabdomyosarcoma cell lines, with caspase-3 activation reaching 24.02% in T98G glioma cells at 10 mg/mL (p<0.05). Cell cycle arrest at S and G2 phases was observed across these lines, and the compound is of interest for cancers with limited therapeutic options; however, these findings have not been replicated in animal tumor models or human clinical trials.

### Is magnoflorine safe to take as a supplement?

Magnoflorine has not been evaluated in human safety trials, so no evidence-based safety guarantee can be made for supplemental use in people. Preclinical data show no cytotoxicity in RAW 264.7 macrophages at tested concentrations, but systematic toxicological studies (LD50, repeated-dose toxicity, genotoxicity, reproductive toxicity) are incomplete or unpublished, and the compound's oral bioavailability, metabolism, and potential drug interactions in humans remain uncharacterized.

### How does magnoflorine differ from berberine?

Both magnoflorine and berberine are isoquinoline-derived alkaloids that co-occur in plants like Tinospora cordifolia and share overlapping anti-inflammatory and metabolic activity through NF-κB and AMPK pathway modulation. The key structural difference is that magnoflorine is classified as a quaternary aporphine alkaloid (rearranged ring system, permanently charged), while berberine is a protoberberine alkaloid; berberine has an extensive human clinical trial database — particularly for blood glucose and lipid management — whereas magnoflorine's evidence base is entirely preclinical, making berberine far better characterized for therapeutic application.

### Does magnoflorine boost immune function, and what research supports this?

In laboratory studies, magnoflorine significantly stimulates macrophage migration and phagocytic activity, outperforming other alkaloids from Tinospora cordifolia in immunostimulatory assays. This suggests a potential role in enhancing innate immune responses, though human clinical trials are limited and results remain preliminary. The mechanism appears to involve activation of immune cells rather than broad immune system modulation.

### How does magnoflorine reduce inflammation at the cellular level?

Research in acute lung injury models shows that magnoflorine reduces inflammatory markers by suppressing TLR4 signaling, inhibiting NF-κB p65 activation, and blocking MAPK phosphorylation—key pathways that drive inflammation. These findings suggest potential benefits in inflammatory conditions, but evidence is currently limited to animal and cell-based studies. Human efficacy and optimal dosing for anti-inflammatory effects remain to be established.

### Who may benefit most from magnoflorine supplementation based on current research?

Individuals interested in immune support and inflammation management may be the primary candidates, based on magnoflorine's demonstrated effects on macrophage activation and inflammatory pathway suppression. However, the evidence base is primarily from laboratory and animal studies rather than human clinical trials. Anyone considering magnoflorine should consult a healthcare provider, particularly those with autoimmune conditions or inflammatory disorders where immune modulation could be relevant.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*